HRMY
Harmony Biosciences HoldingsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.75B
P/E Ratio
12.16
EPS
$2.48
Beta
0.96
52W High
$40.87
52W Low
$25.52
50-Day MA
$29.60
200-Day MA
$32.63
Dividend Yield
—
Profit Margin
16.20%
Forward P/E
9.56
PEG Ratio
—
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Fundamentals
| Revenue (TTM) | $899.11M |
| Gross Profit (TTM) | $688.25M |
| EBITDA | $214.85M |
| Operating Margin | 17.30% |
| Return on Equity | 17.90% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $15.60 |
| Book Value | $15.73 |
| Price-to-Book | 1.92 |
| Price-to-Sales (TTM) | 1.94 |
| EV/Revenue | 1.405 |
| EV/EBITDA | 5.33 |
| Quarterly Earnings Growth (YoY) | -29.50% |
| Quarterly Revenue Growth (YoY) | 16.60% |
| Shares Outstanding | $57.89M |
| Float | $51.73M |
| % Insiders | 11.69% |
| % Institutions | 103.36% |
Historical Volatility
HV 10-Day
33.37%
HV 20-Day
31.07%
HV 30-Day
38.29%
HV 60-Day
32.97%
HV Rank
64.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($44.36 target)
2
Strong Buy4
Buy4
Hold1
Strong SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026